Trial reportPediatrics2019
Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.
Trial report in Pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00841789 (A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Intravenous immunoglobulin for the treatment of Kawasaki disease.The Cochrane database of systematic reviews · 2023Pooled it
- A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.Current rheumatology reports · 2020Pooled it
- Long-Term Outcomes of Coronary Artery Aneurysms in Children With Kawasaki Disease: A Systematic Review.Cureus · 2025Review
- Exploration of common genomic signatures of systemic juvenile idiopathic arthritis and Kawasaki disease.Clinical rheumatology · 2025Article
- Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement.Journal of pediatrics. Clinical practice · 2025Article
- Immunophenotype of Kawasaki Disease: Insights into Pathogenesis and Treatment Response.Life (Basel, Switzerland) · 2025Review
- An Update on Kawasaki Disease.Current rheumatology reports · 2024Review
- Regression effect of renin-angiotensin-aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study.European journal of pediatrics · 2024Observational
- Involvement of IL-17 A/IL-17 Receptor A with Neutrophil Recruitment and the Severity of Coronary Arteritis in Kawasaki Disease.Journal of clinical immunology · 2024Article
- Establishment and validation of a nomogram for coronary artery lesions in children with Kawasaki disease.Frontiers in cardiovascular medicine · 2024Article
- Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.Archives of disease in childhood · 2023Observational
- Management of Multisystem Inflammatory Syndrome in Children: Decision-Making Regarding a New Condition in the Absence of Clinical Trial Data.The Canadian journal of cardiology · 2023Review
- An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children.Diagnostics (Basel, Switzerland) · 2023Review
- Neurological involvement, immune response, and biomarkers in Kawasaki disease along with its pathogenesis, therapeutic and diagnostic updates.F1000Research · 2023Review
- Pharmacogenomics of intravenous immunoglobulin response in Kawasaki disease.Frontiers in immunology · 2023Article
- Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment.PloS one · 2023Article
- Association of Acute Anti-inflammatory Treatment With Medium-term Outcomes for Coronary Artery Aneurysms in Kawasaki Disease.CJC pediatric and congenital heart disease · 2022Article
- Acute phase of Kawasaki disease: a review of national guideline recommendations.European journal of pediatrics · 2022Review
- Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: A case report.SAGE open medical case reports · 2022Article
- The role of mitochondria in the pathogenesis of Kawasaki disease.Frontiers in immunology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
objectivesPatients with Kawasaki disease can develop life-altering coronary arterial abnormalities, particularly in those resistant to intravenous immunoglobulin (IVIg) therapy. We tested the tumor necrosis factor α receptor antagonist etanercept for reducing both IVIg resistance and coronary artery (CA) disease progression.
methodsIn a double-blind multicenter trial, patients with Kawasaki disease received either etanercept (0.8 mg/kg;
resultsIVIg resistance occurred in 22% (placebo) and 13% (etanercept) of patients (
conclusionsEtanercept showed no significant benefit in IVIg resistance in the entire population. However, preplanned analyses showed benefit in patients >1 year. Importantly, etanercept appeared to ameliorate CA dilation, particularly in patients with baseline abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.